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Background: 5-hydroxytryptamine (5-HT) is one of the major neurotransmitters widely distributed in the CNS.
Several 5-HT receptor subtypes have been identified in the spinal dorsal horn which act on both pre- and
postsynaptic sites of excitatory and inhibitory neurons. However, the receptor subtypes and sites of actions as well
as underlying mechanism are not clarified rigorously. Several electrophysiological studies have been performed to
investigate the effects of 5-HT on excitatory transmission in substantia gelatinosa (SG) of the spinal cord. In the
present study, to understand the effects of 5-HT on the inhibitory synaptic transmission and to identify receptor
subtypes, the blind whole cell recordings were performed from SG neurons of rat spinal cord slices.
Results: Bath applied 5-HT (50 μM) increased the frequency but not amplitudes of spontaneous inhibitory
postsynaptic currents (sIPSCs) in 58% of neurons, and both amplitude and frequency in 23% of neurons. The
frequencies of GABAergic and glycinergic mIPSCs were both enhanced. TTX (0.5 μM) had no effect on the
increasing frequency, while the enhancement of amplitude of IPSCs was eliminated. Evoked-IPSCs (eIPSCs) induced
by focal stimulation near the recording neurons in the presence of CNQX and APV were enhanced in amplitude by
5-HT. In the presence of Ba2+ (1 mM), a potassium channel blocker, 5-HT had no effect on both frequency and
amplitude. A 5-HT2A receptor agonist, TCB-2 mimicked the 5-HT effect, and ketanserin, an antagonist of 5-HT2A
receptor, inhibited the effect of 5-HT partially and TCB-2 almost completely. A 5-HT2C receptor agonist WAY 161503
mimicked the 5-HT effect and this effect was blocked by a 5-HT2C receptor antagonist, N-desmethylclozapine. The
amplitudes of sIPSCs were unaffected by 5-HT2A or 5-HT2C agonists. A 5-HT3 receptor agonist mCPBG enhanced
both amplitude and frequency of sIPSCs. This effect was blocked by a 5-HT3 receptor antagonist ICS-205,930. The
perfusion of 5-HT2B receptor agonist had no effect on sIPSCs.
Conclusions: Our results demonstrated that 5-HT modulated the inhibitory transmission in SG by the activation of
5-HT2A and 5-HT2C receptors subtypes located predominantly at inhibitory interneuron terminals, and 5-HT3
receptors located at inhibitory interneuron terminals and soma-dendrites, consequently enhanced both frequency
and amplitude of IPSCs.
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The descending inhibitory system composed mainly of
the periaqueductal gray and consecutive reticular forma-
tion is a structure modulating the nociceptive transmis-
sion from periphery to the central nervous system
(CNS). 5-HT is one of the main neurotransmitters of the
descending system [1,2] which terminates preferentially
on superficial laminae (Laminae I and II), especially the
substantial gelatinosa (SG, lamina II). The SG is com-
posed of interneurons and plays as a local circuit for
processing nociceptive transmission. The 5-HT system
originates from the rostral ventromedial medulla (RVM)
including the nucleus raphe magnus, projects to the
spinal cord through the dorsolateral funiculus and mod-
ulates the nociceptive transmission by interacting with
5-HT receptor subtypes. Exact mechanisms and receptor
subtypes modulating nociceptive transmission are, how-
ever, still obscure [3-6].
The receptor of 5-HT has been classified into seven
distinct classes (5-HT1-5-HT7), some of these are further
divided into subtypes, through pharmacological and mo-
lecular biological studies [7-9]. The 5-HT receptors are
G protein coupled, with exception of the 5-HT3 receptor
which is a ligand gated ion channel [10-12]. Some of the
subtypes are found in the spinal cord, existing at pre-
synaptic or postsynaptic loci of excitatory or inhibitory
SG neurons [13-17]. The autoradiographic studies show
that 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2C, 5-HT3
and 5-HT7 receptors are distributed in the superficial
laminae of the spinal cord [6,18-23]. RT-PCR study
shows that in DRG all subtypes of 5-HT receptors could
be detected except for 5-HT1E, 5-HT2B and 5-HT5B [24].
Although there is controversy regarding the contribution of
5-HT receptor subtypes on the sensory transmission, there
are at least four families of 5-HT receptors (5-HT1, 5-HT2,
5-HT3 and 5-HT7) have been shown to modulate the
nociceptive transmission [25,26]. Behavioral examina-
tions show that stimulation of RVM or intrathecal ad-
ministration of agonists of 5-HT2 or 5-HT3 receptor
mediates antinociception on such as formalin test
[27-30]; paw pressure test [31,32] and hot plate tests [33].
These effects are blocked by intrathecal administration of
5-HT2 or 5-HT3 receptor antagonist. There are also
reports showing an pronociceptive responses of 5-HT
[11,13,34].
γ - aminobutyric acid (GABA) and glycine are major
inhibitory neurotransmitters in the spinal cord [35-37].
Inhibitory synaptic transmission mediated by GABA and
glycine plays an important role in the modulation and
integration of nociceptive sensory transmission [38-40].
GABA-like and glycine-like immunoreactive neurons
exist in the spinal dorsal horn, with fibers and terminals
densely distributed in the SG. GABA and glycine coex-
isting neurons are also observed in the SG [41-45].5-HT activates different subtypes of receptors on the
inhibitory neurons in the spinal dorsal horn, resulting in
the modulation of the nociceptive transmission. Previous
electrophysiological studies [13,14,46] show possible
mechanisms underlying the 5-HT effects in the superfi-
cial dorsal horn. First, 5-HT directly activates postsynap-
tic 5-HT1A receptor and induces an outward current,
inhibiting excitatory neurons and subsequently produ-
cing the analgesic effect [13]. Second, 5-HT induces an
inward current in the small population of SG neurons
through the activation of postsynaptic 5-HT3 receptors
on inhibitory interneurons [13,47]. Third, 5-HT inhibits
glutamate release from C afferent fibers by activating
presynaptic 5-HT1A-like receptors and shows an inhibi-
tory effect on nociception [14]. In this study, not only
inhibitory but also excitatory effects on glutamatergic
transmission are reported, 5-HT transiently inhibits a
frequency of mEPSCs and then enhances. Fourth, 5-HT
acts on inhibitory interneurons and enhances the release
of GABA and/or glycine. The receptor subtypes and sites
of actions as well as underlying mechanism are, however,
not clarified rigorously. In the present study, using the
blind whole cell recording technique, the effects of 5-HT
on the synaptic transmission were studied in SG to iden-
tify the receptor subtypes responsible for the enhance-
ment of the inhibitory transmitter release.
Results
Effects of 5-HT on sIPSCs and mIPSCs in the spinal
substantia gelatinosa
The membrane potential was hold at 0 mV to observe
the effects of 5-HT on sIPSCs in SG. Perfusion of 5-HT
(50 μM) for 60 s resulted in two different effects in the
total of 168 neurons tested. In 58% (98/168) neurons,
significant increase in a frequency of sIPSCs from
4.4 ± 1.8 Hz to 12.9 ± 2.6 Hz (paired t-test, P < 0.01) by
5-HT was observed without a change in a amplitude of
12.6± 1.1 to 13.1± 1.2 pA (P> 0.05, Figure 1A). The same
results were depicted in inter-event intervals and cumula-
tive histograms of the sIPSCs amplitudes (Figure 1B, C).
The averages of the relative frequency and amplitude
were 285% and 104% of the control, respectively
(Figure 1D). While in 23% (36/168) of neurons, 5-HT sig-
nificantly increased both frequency and amplitude of
sIPSCs from 5.2 ± 1.0 Hz and 11.2± 1.3 pA, respectively,
to 16.7± 2.3 Hz (P< 0.001) and 20.4± 1.8 pA (n= 36,
P< 0.01 Figure 1E) and also on the cumulative distribu-
tions (Figure 1F, G). The averages of the relative frequency
and amplitude were 324% and 182% of the control, re-
spectively, (Figure 1H).
Next, the effects of 5-HT on mIPSCs were examined. In
the presence of 0.5 μM TTX, the effect of 50 μM 5-HT
simply increased the frequency but not the amplitude of
mIPSCs (Figure 2A). mIPSCs changed from 1.8 ± 0.3 Hz































































































































Figure 1 Effects of 5-HT on sIPSCs recorded at the holding potential of 0 mV. (A) Bath applied 5-HT (50 μM) increased a frequency but not
amplitude of sIPSCs in 58% of SG neurons. Lower traces show sIPSCs before (left) and after (right) the application of 5-HT in the expanded time
scale. (B) cumulative sIPSCs of the inter-event interval (**P < 0.01, K-S test) and amplitude (C, P > 0.05, K-S test) distributions recorded in control
and in the presence of 5-HT. (D) shows the relative frequency and amplitude compared with the pre-application levels (n = 98). (E) 5-HT (50 μM)
increased the frequency and amplitudes of sIPSCs in 23% of SG neurons. Lower typical traces of sIPSCs observed before, during application of
5-HT. (F) Cumulative probability of the inter-event interval and amplitude (G) of sIPSCs for the neuron in (E). Both distributions of amplitude and
frequency during 5-HT were significantly different from the control (***P < 0.001 and **P < 0.01, respectively, K-S test). (H) The bar graph
normalized results of the frequency and amplitude with the control (n = 36).
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5.2 ± 0.7 Hz (P< 0.01) and 14.7± 2.2 pA, respectively
(P> 0.05, n = 5). The same results were depicted in inter-
event intervals of the mIPSCs and cumulative histograms
of the mIPSCs amplitudes, (Figure 2B, C). The averages of
the frequency and amplitude of mIPSCs to the pre-
application levels of 5-HT were 289% and 104%, respect-
ively (Figure 2D).
The effects of 5-HT on mIPSCs of SG neurons were
further studied in the presence of TTX (0.5 μM) and Ba2+
(1 mM), a potassium channel blocker. The frequency of
mIPSCs in SG neurons was increased markedly by super-
fusion of slices with 1 mM BaCl2. 50 μM 5-HT did not
affect the frequency of mIPSCs further more in this condi-
tion. The IPSCs were from 21.9 ± 3.6 Hz and 22.5 ± 3.7 pA
to 21.7± 4.2 Hz (P>0.05) and 22.4± 4.0 pA (P>0.05, n=7,
Figure 3A), respectively. The same results were depicted in
inter-event intervals and cumulative histograms of the
mIPSCs amplitudes (Figure 3B, C). In the presence of Ba2+,
the averages of frequency and amplitude to the pre-
application levels of 5-HT were 103% and 104%, respect-
ively (Figure 3D). These results suggested that the effects
of 5-HT on inhibitory transmission were concerned withpotassium channels; 5-HT blocked the potassium channels
at the inhibitory interneuron terminals and in some cases
soma-dendrites and subsequently enhance the release of
inhibitory neurotransmitters.
Effects of 5-HT on GABAergic and Glycinergic mIPSCs
Spontaneously occurring mIPSCs were recorded from
SG neurons in the presence of TTX (0.5 μM) and
CNQX (10 μM). GABAergic and glycinergic interneur-
ons are distributed extensively in the superficial dorsal
horn. The effects of 5-HT on the mIPSCs mediated by
GABA or glycine were studied.
In the presence of 2 μM strychnine, 5-HT (50 μM) sig-
nificantly increased the remaining mIPSCs frequency
from 5.2 ± 1.7 Hz to 16.9 ± 2.1 Hz (n = 7, P < 0.01), with-
out affecting of current amplitude from 13.4 ± 2.5 pA to
15.3 ± 2.7 pA (n = 7, P > 0.05). These mIPSCs were
blocked by additional administrations of 10 μM bicucul-
line, confirming that facilitated mIPSCs were GABAergic
(Figure 4A). The averages of the relative frequency
and amplitude were 328% and 114% of the control,
respectively (Figure 4C). Likewise, in the presence of 10


































































Figure 2 Effects of 5-HT on mIPSCs. (A) Effect of 5-HT (50 μM) on mIPSCs in the presence of TTX (0.5 μM). Frequency, but not amplitude of
mIPSCs increased following 5-HT application. Lower typical traces of mIPSCs were taken before (control) and after the onset of 5-HT application
in the presence of TTX. (B, C) Cumulative probability of the inter-event interval and amplitude of mIPSCs were obtained from the neuron (A).
(D) The change in frequency during 5-HT was significantly different from control (**P < 0.01, K-S test), the amplitude during 5-HT was not
































































Figure 3 Effects of 5-HT on mIPSCs in the presence of Ba2+. (A) Typical traces of mIPSCs observed before (control), during, and after the
application of 5-HT (50 μM) in the presence of Ba2+ (1 mM). (B) Cumulative mIPSCs of the inter-event interval and (C) amplitude distributions
compiled from the trace indicated in (A). Both the frequency and amplitude during 5-HT was not different from the control. (D) The bar graph
shows the relative of the mIPSCs frequency and amplitude (paired t-test, P > 0.05, n = 7).







































































































Figure 4 Effects of 5-HT on mIPSCs and eIPSCs of GABAergic and glycinergic interneuron. (A) 5-HT (50 μM) increased the frequency of
GABAergic mIPSCs in the presence of strychnine (St, 2 μM). Subsequent application of bicuculline (Bic, 10 μM) completely eliminated the
remaining mIPSCs. (B) 5-HT (50 μM) also increased the frequency of glycinergic mIPSCs in the presence of bicuculline (10 μM). The facilitated
mIPSCs were eliminated by the application of strychnine (2 μM). The bar graph shows the relative frequency and amplitude for GABAergic
(C, n = 7) and glycinergic (D, n = 5) mIPSCs, respectively. (paired t-test, ** P < 0.01 and * P < 0.05). (E) 5-HT (50 μM) increased the amplitude of
GABAergic (n = 8) eIPSCs with the control in the presence of strychnine (2 μM) together with CNQX (10 μM) and APV (50 μM). (F) 5-HT (50 μM)
also increased the amplitude of glycinergic (n = 7) eIPSCs with the control in the presence bicuculline (10 μM) together with CNQX and APV.
(G) The bar graph shows the relative amplitude for GABAergic and glycinergic eIPSCs (paired t-test, * P < 0.05 and * P < 0.05).
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(P < 0.05), without affecting of current amplitude from
29.3 ± 4.4 pA to 32.2 ± 4.7 pA (n = 5, P > 0.05). This effect
was blocked by simultaneous perfusion of 2 μM strych-
nine and 10 μM bicuculline (Figure 4B). The averages of
the relative frequency and amplitude were 203% and
110% of the control, respectively (Figure 4D). Thus, the
results demonstrated that 5-HT increased the frequen-
cies of both GABAergic and glycinegic mIPSCs. Next,
the effects of 5-HT on evoked GABAergic and glyciner-
gic eIPSCs were studied in the presence of CNQX (10
μM) and APV (50 μM). The results showed that the
amplitudes of both GABAergic (n = 8) and glycinergic
(n = 7) eIPSCs were enhanced. The amplitudes of eIPSCs
were from 54.4 ± 12.4 pA and 91.4 ± 7.4 pA to 91.4 ± 14.5
pA (P < 0.05) and 140.8 ± 9.8 pA (P < 0.05), respectively
(Figure 4E, F). The averages of the relative amplitudewere 168% and 154% of the control, respectively
(Figure 4G).
Identification of 5-HT receptor subtypes in enhancement
of the inhibitory transmitter release
Selective 5-HT receptor agonists and antagonists were
tested to identify which subtypes of 5-HT receptors were
responsible for the enhancement of the release of inhibi-
tory neurotransmitters. 5-HT1A, 5-HT2, 5-HT3 and 5-
HT7 subtypes are shown to expressed in the superficial
dorsal horn neurons and terminals. 5-HT1 and 5-HT7
receptors are coupled to Gi/o, suggesting inhibitory
effects. In fact, the 5-HT-induced membrane hyperpolar-
ization or outward current in SG is mediated by 5-HT1A
[13]. Based on these observations, we evaluated the
effects of agonists and antagonists for 5-HT2, 5-HT3 and
5-HT7 receptor subtypes, in particular 5-HT2A, 5-HT2C
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behavioral studies show that intrathecal administration
of 5-HT2 receptor agonist exhibit analgesic effects
[48,49]. It is, however, still obscure which subtypes of
5-HT2 receptors are involved. We firstly tested each
agonist for all subtypes of 5-HT2 receptors, and then
corresponding antagonists were added to the perfusion
to confirm the responsible subtypes with certainty. The
agonists for 5-HT2A receptor (TCB-2) and 5-HT2B (BW
723C86) as well as 5-HT2C receptors (WAY 161503)
were given to the neurons whose sIPSCs were enhanced
by prior application of 5-HT (Figures 5, 6, 7). The 5-
HT2A receptor agonist, TCB-2 (10 μM) mimicked the
enhancing effects of 5-HT on sIPSCs, increasing the
frequency without affecting the amplitude (Figure 5A).
The frequency and amplitude of sIPSCs were, respect-
ively, from 7.7 ± 4.0 Hz to 18.6 ± 5.6 Hz (n = 7, P < 0.01)
and 19.6 ± 3.2 pA to 20.1 ± 3.4 pA (P > 0.05). The
averages of the relative frequency and amplitude were
242% and 103% of control, respectively (Figure 5C, D).
Perfusion of 5-HT2A receptor selective antagonist,
ketanserin (10 μM), itself had no detectable effect on



















Figure 5 Effects of 5-HT2A receptor agonist and antagonist on sIPSCs
agonist TCB-2 (10 μM) mimicked the enhancing effects of 5-HT (50 μM) on
show sIPSCs before (left) and after (right) the application of TCB-2 in the ex
(10 μM) on the effects of TCB-2 on sIPSCs recorded from the same neuron
the after TCB-2 application in the presence of ketanserin. The bar graph sh
and TCB-2 + ketanserin, respectively (paired t-test, ** P < 0.01, n = 7).markedly reduced the effects of the 5-HT2A agonist. The
averages of the relative frequency and amplitude were
104% and 102%, respectively, of their pre-application
levels (Figures 5C, D). The 5-HT2C receptor agonist,
WAY 161503 (30 μM) also mimicked the 5-HT effect,
enhanced the frequency but not amplitude of sIPSCs
from 5.6 ± 1.0 Hz to 13.7 ± 1.9 Hz (P < 0.01) and 17.9 ± 0.8
pA to 19.1 ± 0.7 pA (Figure 6A, n = 7, P > 0.05), respect-
ively. The averages of the relative frequency and ampli-
tude were 245% and 106% of control, respectively
(Figure 6C, D). In the presence of 5-HT2C receptor
selective antagonist, N-desmethylclozapine (10 μM),
perfusion of WAY 161503 had no effect (Figure 6B).
The frequency and amplitude were 107% (Figure 6C,
P > 0.05) and 104% of control (Figure 6D, P > 0.05), re-
spectively. Figure 7A showed that bath applied 5-HT
increased the frequency but not amplitudes of sIPSCs
from 4.6 ± 0.6 Hz to 11.4 ± 2.0 Hz (P < 0.01, 248% of con-
trol, n = 7), and 18.9 ± 1.3 pA to 20.2 ± 1.5 pA (P > 0.05,
106% of control), while an agonist of 5-HT2B receptor,
BW 723 C86 (10 μM) induced no change in both fre-
quency (to 5.9 ± 0.8 Hz, 115% of control, P > 0.05,



















. (A) Representative recording showing the effects of 5-HT2A receptor
sIPSCs, increasing the frequency, but not amplitude. Lower traces
panded time scale. (B) Shows 5-HT2A receptor antagonist ketanserin
(A). Lower traces shows sIPSCs taken before control (ketanserin) and
ows the relative frequency (C) and amplitude (D) for TCB-2, ketanserin
60 s
50 pA



































N-desme- WAY 161503 +WAY
161503 thylciozapine N-desme-
thylciozapine
Figure 6 Effects of 5-HT2C receptor agonist and antagonist on sIPSCs. (A) Sample trace of sIPSCs recorded before, during and after the
application of WAY 161503 (30 μM). Lower traces show sIPSCs before (left) and after (right) the application of WAY 161503 in the expanded
time scale. (B) In the same (A) neuron, sample trace of sIPSCs recorded before (N-desmethylciozapine 10 μM), during and after the application
of WAY 161503 in the presence of N-desmethylciozapine. Lower traces show sIPSCs before (left) and after (right) the application of
N-desmethylciozapine. The bar graph shows the relative frequency (C) and amplitude (D) for WAY 161503, N-desmethylciozapine and WAY
161503+N-desmethylciozapine, respectively (paired t-test, ** P < 0.01, n = 7).
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from the same neuron. The results demonstrated that
5-HT2A and 5-HT2C receptors might locate in the pre-
synaptic terminals of inhibitory interneurons and respon-
sible for the analgesic role of 5-HT. The 5-HT3 receptors
are also showed to exist in the superficial dorsal horn and
correlates with the analgesic role of 5-HT. Thus we fur-
ther studied a role of 5-HT3 receptor agonist mCPBG
(30 μM). The agonist mimicked the effects of 5-HT to
increase both frequency and amplitude of sIPSCs from
6.8 ± 2.9 Hz and 22.9 ± 1.5 pA to 19.2± 7.6 Hz (292% of
control, p< 0.01) and 37.3± 1.9 pA (165% of control,
p< 0.05, n = 7), respectively (Figure 8A). Both effects
were blocked completely by a 5-HT3 receptor antagonist
ICS-205,930 (10 μM) (Figure 8B). The averages of the fre-
quency and amplitude were 105% and 103% of their pre-
application levels, respectively (Figure 8C, D). In the pres-
ence of TTX (0.5 μM), mCPBG enhanced the frequency
but not amplitude (data not shown). The results suggested
that 5-HT3 receptors were expressed at both on presynap-
tic terminals and soma-dendritic sites of inhibitory inter-
neurons. In addition, we also tested the effect of 5-HT1A/
5-HT7 receptors agonist (8-OH-DPAT 10 μM). Theagonist induced no change in both frequency (to
5.7 ± 0.6 Hz, 107% of control, P>0.05) and amplitude (to
20.2 ± 1.4 pA, 105% of control, n = 7, P>0.05 data not
shown).Discussion
In the present study, using blind whole cell recordings
from adult rat spinal cord slices, the effects of 5-HT on
inhibitory transmission were studied in SG to identify
the receptor subtypes responsible for enhancement of
release of GABA or glycine. The results showed that
5-HT modulated the sensory transmission in SG by the
activation of 5-HT2A, 5-HT2C and/or 5-HT3 receptors,
possibly by reducing the potassium conductance as has
been reported in the variety of CNS neurons.
Substantial numbers of 5-HT receptor subtypes pre-
dominate in the superficial laminae of the spinal dorsal
horn, including 5-HT1A, 5-HT2, 5-HT3 and 5-HT7
[19,49-53]. Among 5-HT receptor subtypes, 5-HT1A and
5-HT7 receptors are coupled to Gi/o, suggesting an inhibi-
tory effects [13,14,54,55]. In contrast 5-HT2 receptor is





































Figure 7 Effects of 5-HT2B receptor agonist and antagonist on sIPSCs. (A) Sample trace of sIPSCs recorded before, during and after the
application of 5-HT (50 μM). Lower traces show sIPSCs before (left) and after (right) the application of 5-HT in the expanded time scale. (B) shows
the same neuron (A) sample trace of sIPSCs recorded before, during and after the application of 5-HT2B receptor agonist BW 723 C86 (10 μM).
Lower races show sIPSCs before (left) and after (right) application of BW 723 C86. The bar graph shows the relative frequency (C), and amplitude
(D) for 5-HT and BW 723 C86, respectively (paired t-test, ** P < 0.01, n = 7).
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effects [13,47,49].
Consistent with this, an agonist for 5-HT1A and 5-HT7,
8-OH-DPAT produced an outward current and did not
show any significant effect on the inhibitory transmission
(data not shown), indicating the 5-HT1A and 5-HT7
receptors might not be responsible for the enhancement
of GABA and glycine releases in the superficial dorsal
horn. We showed that the activation of 5-HT3 receptors
enhanced both frequency and amplitude, and TTX
eliminated the effect on the amplitude, indicating that
the 5-HT3 receptors were expressed at both terminals
and soma-dendritic trees of inhibitory interneurons. It
could not, however, exclude that 5-HT2A and 5-HT2C
receptors were also expressed on both presynaptic term-
inals and soma dendrites; application of the agonists we
used for 5-HT2A and 5-HT2C would not be high enough
to initiate spike firing at somas, because of difference in
density of receptors or efficacy of the agonists.
GABA and glycine are primary inhibitory transmitters
in the spinal dorsal horn and play a critical role in
modulating nociceptive transmission [37,40,56-58]. At
the spinal level, plenty of reports demonstrate that the
analgesic effects via 5-HT2 and 5-HT3 receptors aremediated by GABA [22,59-61], but a few reports con-
cern with glycine. The present our study showed that
not only GABAergic but also glycinergic transmission
were augmented by 5-HT. The inconsistent results
might be correlated with the location of the GABAergic
and glycinergic neurons in the spinal dorsal horn. The
previous studies show that glycinergic transmission are
more prominent in laminae III-IV, whereas GABAergic
transmission seem to predominate in lamina II [45,62].
In contrast to GABAergic neurons, the cell bodies of
glycinergic neurons are preferentially located in lamina
III and deeper laminae [40,42]. The behavioral studies
show that intrathecal administration of 5-HT receptors
agonists generally induce the inhibitory effects on the
nociception, which can be blocked by the corresponding
antagonists [27,29-31,33,63]. Accordingly, these results
suggest that 5-HT2 and 5-HT3 receptors located in the
spinal dorsal horn are involved in the antinociception.
Pile of evidence shows that 5-HT exhibits both inhibi-
tory and excitatory effects with complex mechanisms,
and mechanisms are not fully understood up to now as
there are too many subtypes of 5-HT receptor. The
complexity in the effects of 5-HT might be concerned









































Figure 8 Effects of 5-HT3 receptor agonist and antagonist on sIPSCs. (A) Sample trace of sIPSCs recorded before, during and after the
application of mCPBG (30 μM). Lower traces show sIPSCs before (left) and after (right) the application of mCPBG in the expanded time scale.
(B) In the same neuron from (A), sample trace of sIPSCs recorded before ICS-205,930 (10 μM), during and after the application of mCPBG in the
presence of ICS-205,930. Lower traces show sIPSCs before (left) and after (right) the application of mCPBG in the presence of ICS-205,930 in the
expanded time scale. The bar graph shows the relative frequency (C) and amplitude (D) for mCPBG, ICS-205,930 and mCPBG+ ICS-205,930,
respectively (paired t-test, ** P < 0.01 and *P < 0.05, n = 7).
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show that SG is composed at least of four types neurons,
islet, small islet, vertical and radial neurons. The islet
neurons are inhibitory interneurons and the small islet
neurons include both excitatory and inhibitory inter-
neurons [13,64,65]. It is reported that 5-HT depolarizes
a small population of SG neurons which is morphologic-
ally classified into islet cell type [13].
The previous electrophysiological studies show that 5-HT
exerts different postsynaptic effects on different types of SG
neurons. Depolarization is induced in 6.8% neurons
mimicked by 5-HT3 receptor agonist mCPBG and
block by 5-HT3 receptor antagonist ICS-205,930 [13].
In DRG neurons, the activation of 5-HT receptors also
induces a rapid depolarization. Also slice studies show that
5-HT potentiates the GABA or glycine-induced Cl--current
in the rat sacral dorsal commissural nucleus and superficial
spinal dorsal horn [60,66-68].
In recent studies, behavioral nociceptive tests show
that the 5-HT7 receptor play an antinociceptive role at
the level of the spinal cord [26,54,55]. Immunocyto-
chemical studies found that 5-HT7 receptors arelocalized in the superficial spinal dorsal horn [17,18].
However, our electrophysiological studies did not show
that the 5-HT7 receptor modulated the inhibitory trans-
mission in SG. This result was confirmed by perfusion
of 8-OH-OPAT (10 μM), a mixed 5-HT1A/5-HT7 recep-
tors agonist had no effect on sIPSCs (Data not shown).
Conclusions
The present study demonstrated that 5-HT could en-
hance the release of GABA and glycine by activating the
5-HT2A, 5-HT2C and/or 5-HT3 receptors expressed on
inhibitory interneurons to inhibit sensory transmission.
The 5-HT2A and 5-HT2C receptors predominantly exist
at presynaptic terminals, while the 5-HT3 receptor might
exist at both cell bodies and terminals. It is reported that
5-HT2A receptors also located on soma-dendritic trees
[69]. But our result did not coincide with the report.
The contradiction might be concerned with the distribu-
tion density of the receptors.
In short, the present study provided more evidences to
explain the various mechanisms of 5-HT on modulating
nociceptive transmission in SG of the spinal dorsal horn.
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All the experimental procedures involving the use of ani-
mals were approved by the Ethics Committee on Animal
Experiments, Kyushu University, and were in accordance
with the UK Animals (Scientific Procedures) Act 1986
and associated guidelines. All efforts were made to
minimize the number of animals used for the studies.
Spinal cord slice preparation
Methods for obtaining adult rat spinal cord slices and
for bind patch-clamp recordings from SG neurons were
identical to those described elsewhere [70,71]2. Briefly,
male adult Sprague–Dawley rats (6–7 weeks) were
deeply anesthetized with urethane (1.2g/Kg, ip), and
then thoracolumbar laminectomy was performed. The
lumbosacral spinal cord was removed and placed in a
preoxygenated cold Krebs solution containing (in mM):
NaCl 117, KCl 3.6, CaCl2 2.5, MgCl2 1.2, NaH2PO4 1.2,
NaHCO3 25 and glucose 11 at 1-3°C. The pia-arachnoid
membrane was removed after cutting all the ventral and
dorsal roots. The spinal cord was mounted on a vibra-
tome and then a 500 μm thick transverse or parasagittal
slice was cut. The slice was placed on a nylon mesh in
the recording chamber and then perfused at a rate of
15–20 ml/min with Krebs solution saturated with 95%
O2 and 5% CO2, at 36 ± 1°C.
Patch-clamp recordings from substantia gelatinosa
neurons
Blind whole-cell voltage-clamp recordings were made
from SG neurons with patch pipettes filled with a solu-
tion containing (mM): Cs2SO4 110, tetraethylammonium
(TEA) 5, CaCl2 0.5, MgCl2 2, EGTA 5, HEPES 5 and
ATP-Mg 5 (PH 7.2). Cs2SO4 and TEA were main chemi-
cals which could inhibit the postsynaptic effects of 5-HT
on the K+ channels, and enabled us to investigate the
presynaptic effects on IPSCs by 5-HT. Recorded neurons
were identified as SG by their locations and morphologic
features. SG was easily identifiably as a relatively translu-
cent band across the dorsal horn. In some instances,
neurobiotin was injected in the recorded neurons
through electrodes. After completing experiments, the
recorded neuron were stained and their morphological
features were compared with those reported previously
[13,64,65,72]. Monosynaptic IPSCs were evoked in the
presence of a non-NMDA-receptor antagonist CNQX,
and an NMDA-receptor antagonist APV, at a frequency
of 0.2 Hz by a focal monopolar silver electrode (50 μm
diameter), insulated except for the tip, located within 150
μm of the recorded neurons. Signals were acquired with
a patch clamp amplifier (Axopatch 200B, Molecular
Devices, Union City, CA, USA). The data were digitized
with an analog-to-digital converter (digidata 1321A, Mo-
lecular Devices, CA, USA), and stored and analyzed witha personal computer using the pCLAMP data acquisition
program (version 8.2, Molecular Devices, CA, USA). The
recordings were made under the voltage-clamp mode at
holding membrane potentials of 0 mV to isolate IPSCs.
At this potential the glutamate-mediated excitatory post-
synaptic currents (EPSCs) were negligible, because of a
reversal potential of EPSCs. In fact, no remaining synap-
tic currents were observed in the presence of antagonists
for GABA and glycine receptors [70]. Frequencies and
amplitudes of spontaneous IPSCs (sIPSCs) and miniature
IPSCs (mIPSCs) in the presence of TTX (0.5 μM) were
measured automatically with MiniAnalysis software
(Synaptosoft, Decatur, GA). The frequency of IPSCs was
further confirmed by their shapes with eyes.
Drug application
Drugs dissolved in Krebs solution were applied to the sur-
face of the spinal cord by exchanging solutions via a
three-way stopcock without any change in both perfusion
rate and temperature. The time necessary for the solution
to flow from the stopcock to the surface of the spinal cord
was approximately 5 s and the solution in the recording
chamber was completely exchanged with a drug contain-
ing solution within 15 s. The drugs used were 5-HT
hydrogen maleate (Sigma, St. Louis, MO, USA), tetrodo-
toxin (TTX) (Wako, Osaka, Japan), 6-cyano-7-nitroqui-
noxaline-2,3-dione (CNQX) (Sigma), DL-2-amino-5-
phosphonovaleric acid (APV) (Sigma), BaCl2 (Sigma),
strychnine (Sigma), bicuculline (Sigma), 4-bromo-3,6-
dimethoxybenzocyclobuten-1-yl) methylamine hydrobro-
mide (TBC-2) (Tocris Cookson, Bristol, UK), ketanserin
(Sigma), α-methyl-5-(2-thienylmethoxy)-H-indole-3-etha-
namine hydrochloride (BW723C86) (Sigma), 8,9-dchloro-
2,3,4 4a-tetrahydro-1H-pyrazino[1,2-a] quinoxalin-5(6H)-
one hydrochloride (WAY161503) (Tocris), 8-chloro-11-(1-
piperazinyl)-5H-dibenzo[b,e][1,4]diazipine (N-desmethyl-
clozpine) (Tocris), 1-(m-chlorophenyl)-biguanide (mCPBG)




All the data were expressed as the mean ± S.E.M. Statis-
tical significance was determined as P < 0.05 using the
paired t-test. Cumulative probability plots were con-
structed for sIPSC amplitude and frequency and were
compared, under different experimental conditions,
using the Kolmogorov-Smirnov test. In all cases, n refers
to the number of neurons studied.
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